82 related articles for article (PubMed ID: 15590391)
21. Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Jia H; Ge F; Lu X; Zeng H; Li L; Chen Z; Lu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):784-91. PubMed ID: 20818069
[TBL] [Abstract][Full Text] [Related]
22. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
23. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
[TBL] [Abstract][Full Text] [Related]
25. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
26. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
Gambacorti-Passerini C; le Coutre P; Mologni L; Fanelli M; Bertazzoli C; Marchesi E; Di Nicola M; Biondi A; Corneo GM; Belotti D; Pogliani E; Lydon NB
Blood Cells Mol Dis; 1997 Dec; 23(3):380-94. PubMed ID: 9446752
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
30. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
31. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
[TBL] [Abstract][Full Text] [Related]
32. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
33. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
34. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
35. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
36. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma.
Mao X; Li X; Sprangers R; Wang X; Venugopal A; Wood T; Zhang Y; Kuntz DA; Coe E; Trudel S; Rose D; Batey RA; Kay LE; Schimmer AD
Leukemia; 2009 Mar; 23(3):585-90. PubMed ID: 18754030
[No Abstract] [Full Text] [Related]
37. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
38. Measurement of separase proteolytic activity in single living cells by a fluorogenic flow cytometry assay.
Haaß W; Kleiner H; Müller MC; Hofmann WK; Fabarius A; Seifarth W
PLoS One; 2015; 10(8):e0133769. PubMed ID: 26267133
[TBL] [Abstract][Full Text] [Related]
39. Thiasyrbactins Induce Cell Death
Pierce MR; Bakas NA; Pirrung MC; Bachmann AS
Anticancer Res; 2018 Oct; 38(10):5607-5613. PubMed ID: 30275178
[TBL] [Abstract][Full Text] [Related]
40. [Macrocalin A induces apoptosis of multiple myeloma U266 cells through inhibiting the proteasome].
Lu LN; Feng LQ; Lu YP; Xia J; Qiu LN; Shi H; Wang WZ; Zhou YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1486-91. PubMed ID: 24370034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
